A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD)
Conditions
Diseases of the Nervous System | Mental Health & Behavioral Research | Alzheimer's Disease
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
Brief Summary:
This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.
Alzheimer’s Disease Research Unit (ADRU) - http://www.alzheimers.yale.edu
- Ages50 years - 90 years
- GenderBoth
- Trial withEisai Pharmaceuticals
- Start Date10/22/2019
- End Date02/23/2022
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated03/15/2020
- Study HIC#2000026162